Auj. à 10:11
Glaucoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017 report is an essential source of information and analysis on the global glaucoma therapeutics market. The report identifies the key trends shaping and driving the global glaucoma therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global glaucoma therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.
The Glaucoma Market Is Forecast to Show a Decline in Growth Rate Due to a String of Patent Expiries
The glaucoma market is predicted to witness major revenue depletion over the next few years due to a string of patent expiries. Pfizers Xalatan (latanoprost) is the most prescribed drug for the treatment of glaucoma. The authors' analysis suggests that the global glaucoma therapeutics market was worth $3.9 billion in 2009. The market is forecast to decline with a Compound Annual Growth Rate (CAGR) of 4.7%, which is mostly due to the patent expirations of branded drugs. The market will be flooded with generic version of these branded drugs, which could impact the glaucoma therapeutics market.
Glaucoma Market is Expected to Witness Entry of Me-Toos and Product Extensions in the Near Future
The glaucoma market will be subjected to generic erosion, which could impact overall market revenues despite the increase in disease prevalence and treatment seeking rates. The interesting fact to note is that products which are expected to enter the market are either me-toos or product extensions, which will not bring about any significant improvements in terms of safety and efficacy. Therefore, the only factor which could drive the market would be the cost of the product. As a result, generics are predicted to govern the market for glaucoma drugs over the next few years. The CAGR for 2001 to 2009 was 1.7% and is expected to nose dive to a negative CAGR of -4.7% between 2009 and 2017 because of the possible impact of generics entering the market.
GlobalData, the industry analysis specialist, has released its new report, Glaucoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017. The report is an essential source of information and analysis on the global glaucoma therapeutics market. The report identifies the key trends shaping and driving the global glaucoma therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global glaucoma therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Our team of industry experts.
The glaucoma market is predicted to witness major revenue depletion over the next few years due to a string of patent expiries. Pfizer's Xalatan (latanoprost) is the most prescribed drug for the treatment of glaucoma. Our analysis suggests that the global glaucoma therapeutics market was worth $3.9 billion in 2009. The market is forcast to decline with a Compound Annual Growth Rate (CAGR) of 4.7%, which is mostly due to the patent expirations of branded drugs. The market will be flooded with generic version of these branded drugs, which could impact the glaucoma therapeutics market.
Scope
•The report provides information on the key drivers and challenges of the glaucoma therapeutics market. Its scope includes:
•Annualized global glaucoma therapeutics market revenues data from 2001 to 2009, forecast for eight years to 2017.
•Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as factor Xa inhibitors, direct thrombin inhibitors, and gap junction modifiers, along with other novel anti-arrhythmic drugs.
•Analysis of the current and future competition in the global glaucoma therapeutics market. Key market player covered are NicOx, Bausch and Lomb, Novagali Pharma, CeNeRx Biopharma, Aerie Pharma, Allergan and Merck.
•Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
•Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the glaucoma therapeutics market.
Reasons to buy
•The report will enhance your decision making capability. It will allow you to:
•Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
•Develop business strategies by understanding the trends shaping and driving the global glaucoma therapeutics market.
•Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global glaucoma therapeutics market in future.
•Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
•Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
•Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
•What's the next big thing in the global glaucoma therapeutics market landscape? Identify, understand and capitalize.
Key Topics Covered:
•1 Summary
•2 Introduction
•3 Glaucoma Therapeutics: Market Characterization
•4 Glaucoma Market: Competitive Assessment
•5 Glaucoma: Pipeline Assessment
•6 Glaucoma Therapeutics Market: Implications for Future Market Competition
•7 Glaucoma Market: Future Players in the Glaucoma Market
•8 Glaucoma Market: Appendix
Companies Mentioned:
•NicOx SA and Bausch and Lomb
•Merck (MSD) and Santen Pharmaceuticals, Japan
For more information visit
Glaucoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017 - Market Research Reports - Research and Markets.
ogni volta che si migliora una molecola le big pharma tendono a massacrare la nuova entità fiutando il pericolo imminente e grazie agli organi di controllo compiacenti bocciano tutte le nuove proposte
di questo passo si fermerà anche la ricerca poichè chi sarà disposto a rischiare milioni di $ per un nulla di fatto
